Clinical commissioning policy: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

Document first published:: 6 November 2023
Page updated:: 6 November 2023
Topic:: Specialised commissioning
Publication type:: Policy or strategy

Obinutuzumab is recommended to be available off-label as a routine commissioning treatment option as elective therapy to prevent immune TTP relapse in patients who are intolerant or refractory to rituximab within the criteria set out in this document.

Document

$Clinical commissioning policy: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)$

Clinical commissioning policy: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

PDF
221 KB
9 pages

Document

$Clinical priorities advisory group report: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)$

Clinical priorities advisory group report: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

PDF
171 KB
7 pages

Document

$Clinical panel report: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)$

Clinical panel report: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

PDF
119 KB
3 pages

Document

$Engagement report: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)$

Engagement report: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

PDF
126 KB
5 pages

Document

Evidence review: Obinutuzumab for acute immune thrombotic thrombocytopenic purpura

PDF
202 KB
25 pages

Document

Evidence review: Obinutuzumab for prevention of acute immune thrombotic thrombocytopenic purpura

PDF
269 KB
29 pages

Document

$Equality and Health Inequalities Impact Assessment (EHIA): Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)$

Equality and Health Inequalities Impact Assessment (EHIA): Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

PDF
125 KB
12 pages

Cookies on the NHS England website

Clinical commissioning policy: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

Clinical priorities advisory group report: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

Clinical panel report: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

Engagement report: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

Evidence review: Obinutuzumab for acute immune thrombotic thrombocytopenic purpura

Evidence review: Obinutuzumab for prevention of acute immune thrombotic thrombocytopenic purpura

Equality and Health Inequalities Impact Assessment (EHIA): Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)